Walden Group Healthcare M&A Blog

  • Select M&A Deals and Terminations in the Age of Coronavirus

    5/18/2020
    Select M&A Deals and Terminations in the Age of Coronavirus (Terms not announced unless specified)     Beaver-Visitec Acquires Ophthalmic Viscoelastic Device Assets from Croma-Pharma (Austria)     Smiths Medical Acquires Access Scientific (US)     Zhuhai Baolian Asset Management Plans to Acquire Shanghai Kehua Bio-Engineering (China)...
    Read More
  • The Walden Group Releases 2020 Q1 Strategic Healthcare M&A Report

    5/4/2020
    The Walden Group, an M&A advisory firm focused on the healthcare industry, has published its complimentary 2020 Q1 Strategic Healthcare M&A Report, available for download on its website, www.waldenmed.com.  The report includes analysis of more than 60 M&A transactions announced of closed in Q1, among several other key developments...
    Read More
  • Big Pharma Invest Deeper into Cancer Treatment

    1/2/2020
    In early December 2019, two of the biggest pharmaceutical companies announced multibillion-dollar deals aiming at bolstering their oncology pipeline.   Merck & Co. Inc. is paying $2.5b to acquire ArQule, Inc, whose lead investigational candidate is an oral Bruton’s tyrosine kinase (BTK) inhibitor currently in a Phase II dose-expansion...
    Read More
  • Orthopedic and Spine Sector Consolidations Tighten the Market

    12/11/2019
    Stryker recently announced purchase of Wright Medical for $4b purchase (4.5x revenue and 38.5x EBITDA) is yet another example of the consolidation within the orthopedic and spine sectors.  As reimbursement levels become tighter and margins are challenged, economies of scale become paramount. Wright Medical is a recognized leader in upper...
    Read More
  • Novartis is paying $9.7b to acquire The Medicines Company for a Potentially Blockbuster Cholesterol-Lowering Therapy

    12/03/2019
    The Medicines Company is developing "inclisiran",  a potentially transformational medicine that reimagines the treatment of atherosclerotic heart disease and familial hypercholesterolemia. With tens of millions of patients at higher risk of cardiovascular events from high LDL-C, inclisiran could contribute significantly to improved patient...
    Read More